Clinical Practice Guidelines for the Management of Arterial Hypertension in Primary Healthcare

Objectives

This Ministry of Health and Prevention primary-care guideline adapts international hypertension guidance for the United Arab Emirates, providing pragmatic, evidence-based recommendations to prevent hypertension, improve early detection and diagnosis, support effective treatment, and increase blood-pressure control.[1][2]It supports the United Arab Emirates national non-communicable disease plan 2017–2021, aligned with the World Health Organization action plan 2015–2025 and the Sustainable Development Goals 2030.[2]

• Reduce the prevalence of raised blood pressure by 25% by 2025, a strategic indicator in the Ministry of Health and Prevention strategic plan.[2]
• Detect predominantly asymptomatic hypertension through structured population screening or opportunistic blood-pressure measurement; establish diagnosis and grade; identify secondary causes; assess total cardiovascular risk; and detect hypertension-mediated organ damage.[3]
• Assess hypertension comprehensively by identifying cardiovascular and renal risk factors, lifestyle factors, comorbidities, target-organ damage, and established cardiovascular or renal disease.[4][5][6]
• Reduce long-term total cardiovascular disease risk through combined lifestyle interventions and pharmacological blood-pressure treatment.[7]People with established cardiovascular disease, diabetes or chronic kidney disease are classified as high risk and require intensive lifestyle intervention and appropriate drug therapy.[7]
• Promote lifestyle measures including physical activity, healthy weight, a diet rich in fruit, vegetables, low-fat dairy products, whole grains and plant-based protein, reduced salt intake, tobacco cessation, moderation or avoidance of alcohol, and stress management where relevant.[8][9]
• Achieve risk- and age-appropriate blood-pressure and lipid targets, prevent cardiovascular events and mortality, and use statins and antiplatelet therapy according to cardiovascular-risk and secondary-prevention indications.[10][11][12]
• Identify potentially treatable secondary hypertension early, especially in younger patients, and distinguish hypertensive emergencies requiring immediate intensive care from hypertensive urgencies generally managed without admission.[13][14]

Implementation

The guideline is designed as a practical delivery tool for primary healthcare providers in Ministry of Health and Prevention facilities.[1]It adapts the 2018 European Society of Cardiology and European Society of Hypertension guidance and was developed with family-medicine, internal-medicine and cardiology expertise, including national non-communicable disease programme coordination across several emirates.[1][2]Delivery combines accurate measurement, risk-based clinical assessment, lifestyle support, medicines management, follow-up, referral and specialist care when required.[15][16][17]

• Strengthen measurement quality by training health professionals, periodically reviewing performance, and using validated, maintained and recalibrated devices.[18]Standardise office measurement through appropriate patient preparation, cuff selection and positioning, bilateral arm measurement at the first visit, three readings one to two minutes apart, and averaging of the final two readings.[18]
• Combine office measurement with home blood-pressure monitoring and ambulatory blood-pressure monitoring, particularly for a new diagnosis where ambulatory monitoring is available and for suspected white-coat, masked or resistant hypertension.[19][3]Use validated semi-automatic home devices, preferably over six to seven consecutive days, with morning and evening readings.[19]
• Record each adult’s blood pressure in the medical record and ensure that people know their readings.[3]Repeat measurement at intervals based on baseline blood pressure, ranging from at least every five years for optimal blood pressure to annual assessment for high-normal blood pressure or masked hypertension.[3]
• Conduct a comprehensive history, examination and investigation programme covering cardiovascular and renal risk, lifestyle, symptoms of organ damage, possible secondary hypertension, pregnancy history and current or previous antihypertensive treatment.[4]Use routine laboratory tests, urine analysis, electrocardiography and fundoscopy, with further targeted investigations where secondary hypertension is suspected.[20]
• Initiate treatment promptly alongside lifestyle change for grade 2 or 3 hypertension.[9]For grade 1 hypertension, begin with lifestyle intervention in low- to moderate-risk patients without organ damage and add medication after three to six months if hypertension persists, while treating high-risk patients or those with organ damage promptly.[9]Prefer single-pill combination therapy for most patients and avoid combining angiotensin-converting enzyme inhibitors with angiotensin-receptor blockers.[21]
• Support adherence by simplifying regimens, using fixed-dose combinations or pill dispensers where appropriate, fitting treatment into daily routines, involving patients and families, and assessing adherence at every visit.[12]Review patients monthly after treatment initiation until targets are achieved, then every three to six months, with more frequent review for complicating comorbidities.[12]
• Monitor serum potassium and creatinine at least annually, assess micro-albuminuria and screen for diabetes and dyslipidaemia annually, with renal-function and potassium checks within two weeks of starting an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker.[12]Refer to a hypertension specialist if therapeutic goals are not achieved within six months.[12]
• Manage most hypertension in primary care, referring for hospital-based evaluation where secondary, severe or treatment-resistant hypertension is suspected; where organ damage needs detailed assessment; or where onset is sudden, postural hypotension is present, or organ damage progresses rapidly.[17]Provide emergency referral and inpatient-level care for hypertensive emergencies, including continuous cardiac and haemodynamic monitoring and titratable intravenous treatment.[14][17]
• Engage multiple stakeholders through guideline implementation, public awareness programmes and salt-reduction legislation, while basing individual treatment decisions on consultation between the responsible health professional, patient and, where appropriate, caregiver.[2]The available material does not specify budgets, financing arrangements, a programme-wide reporting system, or named accountability bodies beyond the strategic prevalence-reduction indicator.[2][17]

Monitoring & Evaluation

Monitoring is primarily clinical and patient-level, centred on accurate blood-pressure measurement, repeated assessment, treatment targets, cardiovascular-risk stratification, laboratory monitoring and follow-up. At programme level, the Ministry of Health and Prevention strategic plan identifies a 25% reduction in raised-blood-pressure prevalence by 2025 as a strategic indicator; the supplied material does not set out a comprehensive reporting, surveillance, audit or accountability framework.[2]

• Measure blood pressure accurately by training health professionals, periodically reviewing their performance, and using validated, maintained and regularly recalibrated devices.[18]
• Standardise office measurement by preparing the patient, using an appropriate cuff and positioning, measuring both arms at the first visit, taking three readings one to two minutes apart, averaging the final two, and checking standing blood pressure for orthostatic hypotension.[18]
• Use office, home and ambulatory thresholds to diagnose hypertension: above 140/90 mmHg in the office; above 135/85 mmHg for daytime ambulatory or home averages; above 120/70 mmHg at night; and above 130/80 mmHg for 24-hour ambulatory averages.[19]
• Validate ambulatory monitoring through a usual 24-hour recording period, measurements at 15 to 30-minute intervals and at least 70% usable readings; use ambulatory monitoring for a new diagnosis where available.[19]
• Record every adult’s blood pressure in the medical record and ensure that individuals know their readings.[3]
• Repeat screening at least every five years for healthy people with optimal office blood pressure below 120/80 mmHg, every three years for normal blood pressure of 120-129/80-84 mmHg, and annually for high-normal blood pressure of 130-139/85-89 mmHg or masked hypertension.[3]
• Differentiate white-coat hypertension, defined as raised untreated office readings with normal out-of-office readings, from masked hypertension, defined as normal untreated office readings with raised home or ambulatory readings.[3]
• Assess total cardiovascular risk using the Ministry of Health and Prevention adaptation of the World Health Organization and International Society of Hypertension prediction chart for people aged 40 years and over without established cardiovascular disease.[7]
• Assess renal and hypertension-mediated organ damage through measures including albuminuria, estimated glomerular filtration rate, electrocardiographic or echocardiographic left-ventricular hypertrophy, ankle-brachial index, retinopathy, and established cardiovascular or renal disease.[20][5][6]
• Assess treatment against age- and condition-specific office blood-pressure targets, including for people with diabetes, coronary artery disease, stroke or transient ischaemic attack, and chronic kidney disease.[10]
• Monitor cardiovascular-risk management through low-density lipoprotein cholesterol goals, including below 3.0 mmol/L for low-to-moderate risk, below 2.6 mmol/L for high risk, and below 1.8 mmol/L for very-high-risk people treated with statins.[11][12]
• Assess tobacco use at every visit, assess adherence at every visit, and monitor whether blood pressure remains elevated after lifestyle intervention.[9][12]
• Review patients monthly after treatment initiation until the blood-pressure goal is reached, with more frequent review for complicating comorbidities; extend follow-up to every three to six months after control is achieved.[12]
• Refer to a hypertension specialist when therapeutic goals, including blood-pressure control, have not been achieved within six months.[12]
• Monitor serum potassium and creatinine at least annually, measure micro-albuminuria annually where there is no renal impairment and more frequently with renal disease or diabetes, and screen annually for newly diagnosed diabetes and dyslipidaemia.[12]
• Check renal function and potassium within two weeks of starting an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.[12]
• Confirm suspected resistant hypertension with ambulatory or home monitoring after confirming adherence, and investigate possible white-coat effects, measurement error, interfering substances and secondary causes.[22]
• Monitor hypertensive emergencies using continuous cardiac and haemodynamic monitoring, frequent urine-output measurement and neurological assessment.[14]
• Support home monitoring through seven days of morning and evening records, with two blood-pressure and pulse readings in each period, and by checking the home device against a health-centre reading.[17]

Reported population measures provide baseline context for the national target: hypertension prevalence among adults aged 18 years and over was reported as 26.3% in the 2014 World Health Organization report and 28.8% in the 2018 United Arab Emirates national health survey. Sex-disaggregated estimates were 27.5% for males and 23.3% for females in 2014, and 37.8% for males and 19.5% for females in 2018.[2]

No formal reporting timetable, data-flow arrangement, surveillance architecture, independent evaluation methodology, audit requirement, named accountable body or corrective-action process is specified beyond the strategic prevalence-reduction indicator and the clinical monitoring measures described above.[2][19][3][12][22][14][17]

Costing & Financing

The supplied material does not specify a budget, costed implementation plan, financing source, resource-mobilisation arrangement, funding gap or economic assumption for hypertension prevention, diagnosis, treatment, monitoring or referral.[1][2][18][19][3][12][14][17][23]

• Identify no quantified allocation for workforce training, validated and recalibrated blood-pressure devices, ambulatory or home monitoring, laboratory testing, medicines, specialist referral, public awareness, salt-reduction legislation or emergency care.[2][18][19][12][14]
• Refer users to national formularies for medicine availability and recommended doses, including single-pill and free combinations, without specifying medicine prices, reimbursement arrangements or procurement financing.[21]
• Leave unspecified the resources required to deliver frequent follow-up, adherence assessment, renal and potassium testing, cardiovascular-risk assessment, and specialist management of resistant hypertension.[12][22]